Economic Evaluation of Population-Based BRCA1/BRCA2 Mutation Testing across Multiple Countries and Health Systems
This recent paper, an analysis of the economic value of BRCA genetic screening of the whole population used the Quality Adjusted Life Year (QALY) as a measure of cost. The QALY measures what price is reasonable for an extra year of life without disease. The amount is indeterminate and varies in different countries.
Society values a QALY less than an individual; Drug companies when promoting their product usually apply a QALY of about $45,000. Non-commercial health interventions may have two QALYs; the social value at about $20,000, the individual payer $25,000.
The study used the non-commercial criteria and found that in advanced economies the result from whole of population genetic screening for BRCA was cost saving, meaning the economic justification is sound.
No comments:
Post a Comment